Renibus Therapeutics Announces Participation At The 36th Annual Oppenheimer Life Sciences Conference

Renibus Therapeutics, a clinical‑stage biopharmaceutical company focused on preventing and treating cardiac, renal, and metabolic diseases, announced it will participate in the 36th Annual Oppenheimer Life Sciences Conference February 25‑26, 2026, with Chief Medical Officer Bhupinder Singh presenting virtually on February 25 at 2:40 pm ET and management holding one‑on‑one investor meetings. The announcement highlights the company’s ongoing clinical programs, including its Phase 3 development of veverimer for metabolic acidosis in chronic kidney disease and evaluation of RBT‑1 following its PROTECT Phase 3 trial.

Learn More